Kat6 Inhibitor | YesPress

Browse all tags

ceo2909 saas2415 ai1731 fintech1456 founder1251 b2b1079 b2b saas888 san francisco823 co-founder816 san-francisco799 y combinator769 startup734 machine learning665 enterprise software625 stanford603 series a590 venture capital577 biotech543 cybersecurity535 healthtech479 new york startup469 ai agents452 enterprise-software447 generative ai437 digital health434 agentic ai393 silicon-valley389 d2c386 silicon valley381 ecommerce379 machine-learning373 startup founder360 california351 entrepreneur350 new york347 edtech343 venture-capital340 climate tech328 newsletter321 mit302 proptech302 robotics294 y-combinator281 san francisco startup278 enterprise ai276 series b273 developer tools264 computer vision255 oncology252 open-source247 series-a244 harvard242 supply chain241 sustainability240 iot232 enterprise229 biotechnology224 compliance224 workflow automation223 telehealth217 founder ceo216 healthcare213 insurtech212 developer-tools211 blockchain210 devops208 medical devices206 series-b206 logistics199 forbes 30 under 30194 llm193 uc berkeley189 author188 generative-ai188 clean energy187 deep tech187 web3185 cloud184 a16z183 drug discovery182 b2c176 life sciences176 artificial intelligence175 no-code175 manufacturing174 payments170 general partner169 healthcare ai169 crm168 serial entrepreneur167 seed funding164 open source162 automation160 podcast160 hardware159 digital transformation158 unicorn158 marketplace152 predictive analytics152 infrastructure151

Often tagged with

oncology1 breast-cancer1 biotech1 biopharmaceutical1 clinical-stage1 drug-development1 palazestrant1 serd1 ceran1 estrogen-receptor1 metastatic-breast-cancer1 precision-medicine1 targeted-therapy1 nuclear-receptors1

Tagged: kat6-inhibitor

1 result

Sort

Health · Enterprise

Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.

oncology · breast-cancerRead →